PliNOSa® K-1600 Assay Kit

An Innovation for Sepsis Screening

TCS Biosciences Ltd is pleased to announce our partnership with R&D Antibodies. R&D Antibodies has delivered high quality research antibodies and immunoassays to the life sciences and research markets since 1984.

The PliNOSa® K-1600 Assay Kit is a novel in vitro diagnostic immunoassay for the early identification of sepsis.

The PliNOSa® test detects inducible Nitric Oxide Synthase (iNOS) on microvesicles in plasma, an innovation in sepsis disease pathology.

The PliNOSa® test can help physicians make better and more informed choices for improved patient management.

iNOS has specifically been implicated in sepsis, severe sepsis and septic shock. The PliNOSa® K-1600 assay kit provides accurate measurement of circulating iNOS concentrations in plasma samples via a chemiluminescent sandwich EIA. Each kit is for 96 tests.

PliNOSa® K-1600 assay kit
iNOS plasma

PliNOSa® features:

  • Detects circulating iNOS in plasma.
  • Novel biomarker directly involved in sepsis pathology.
  • The assay is CE marked.
  • Standards and controls are provided.
Test benefits:
  • Can identify patients at risk as early as 48 hours before clinical symptoms appear.
  • Easy to use ELISA test with 8-well strips (x12) for efficiency.
  • Compatible with most EIA washers.
The kit includes:
  • 12 x 8 well strips with immobilized anti-iNOS capture monoclonal antibody
  • HRP-labelled anti-iNOS detection monoclonal antibody
  • Wash buffer
  • Assay buffer
  • Diluents
  • Standards and controls
Table 1 - Organ Dysfunction Associated with Sepsis in Severely Injured Trauma Patients
N = 187 Heart, Lung or Kidney Dysfunction
Present Absent
iNOS Positive 107 5
Negative 15 60
Sensitivity = 88% PPV = 96%
Specificity = 92% NPV = 80%

The Sepsis Pathology via Microvesicles

The Sepsis Pathology Via Microvesicles

Until now, sepsis has been an intractable disease that has baffled medical researchers for centuries.

Biochemical markers such as procalcitonin (PCT), IL-6, lactate and CRP have lacked the necessary specificity and sensitivity. These assays often fail to help physicians and clinicians to identify at-risk patients who are progressing down the sepsis pathway.

The PliNOSa® test helps physicians assess a patient's risk of developing sepsis as much as 48 hours before recognisable symptoms appear.

Contact us for more information

Online Catalogue

fiftieth
fiftieth
We would love to hear your feedback...

Ways to contact us

t: +44 (0)1296 714222
f: +44 (0)1296 714806

Botolph Claydon, Buckingham, MK18 2LR, United Kingdom

Follow us

Follow us on Twitter Follow us on Twitter

TCS Biosciences Ltd
t: +44 (0)1296 714222  •  f: +44 (0)1296 714806  •  e: sales@tcsgroup.co.uk
Botolph Claydon, Buckingham, MK18 2LR, United Kingdom

Design: StudioEighty | Webmaster: AnnWebCom
back to top